| Ytd | -77.67% | |
| 1y | -90.95% |
| Open | 1.01 | Prev Close | 0.98 | Low | 0.98 | High | 1.04 | Mkt Cap | 2.11M |
| Vol | 104.72K | Avg Vol | 149.52K | EPS | -2.56 | P/E | -0.39 | Forward P/E | -5.83 |
| Beta | 1.20 | Short Ratio | 13.56 | Inst. Own | 15.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.86 | 200-d Avg | 3.84 | 1yr Est | 12.75 |
FBLG News
Patent has potential for applications beyond diabetes, including other cell and tissue transplantati
Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting
Top Wall Street analysts changed outlook on top names. Complete view of analyst rating changes, incl
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On t
Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trived
Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOU
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a cli
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds up
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patient
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC6
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and s
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potentia
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulc
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”),
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result
